US 12,064,532 B2
Ovarian-derived hydrogels for biomedical and biotechnology applications
Bryan Brown, Pittsburgh, PA (US); Michael Buckenmeyer, Pittsburgh, PA (US); Aleksandar Rajkovic, Pittsburgh, PA (US); and Yonghyun Shin, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed by UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed on Jul. 25, 2022, as Appl. No. 17/872,467.
Application 17/872,467 is a continuation of application No. 15/449,742, filed on Mar. 3, 2017, granted, now 11,458,224.
Claims priority of provisional application 62/303,993, filed on Mar. 4, 2016.
Prior Publication US 2022/0395612 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/38 (2006.01); A61L 27/36 (2006.01); A61L 27/52 (2006.01); C12N 5/075 (2010.01)
CPC A61L 27/3804 (2013.01) [A61L 27/3604 (2013.01); A61L 27/3687 (2013.01); A61L 27/3691 (2013.01); A61L 27/52 (2013.01); C12N 5/0609 (2013.01); A61L 2400/06 (2013.01); A61L 2430/40 (2013.01); C12N 2500/84 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A lyophilisate comprising a decellularized ovarian tissue, wherein the lyophilisate comprises an ovarian-derived extracellular matrix in a concentration between 1 mg/ml to 10 mg/ml, at least one biocompatible crosslinking reagent selected from the group consisting of lysyl oxidase, genipin, ribose, rose bengal, and combinations thereof, wherein the lyophilisate includes adhesion sites for a follicle.